BiomX Inc. (NYSE:PHGE) is a clinical-stage company that develops phage therapies targeting specific pathogenic bacteria. The company is preparing for a reverse stock split on November 25, 2025. This move will consolidate every 19 shares into 1 new share, a decision approved by stockholders at the 2025 Annual Meeting. The reverse stock split aims to adjust the share price and improve the stock's marketability.
As highlighted by the company's announcement, the Board of Directors finalized the one-for-nineteen ratio on November 13. The stock will continue trading under the symbol "PHGE" on the NYSE American, with a new CUSIP number of 09090D 509. Currently, PHGE's stock price is $0.29, marking an 8.31% decrease with a change of -$0.02. The stock has fluctuated between $0.29 and $0.31 today.
Over the past year, it reached a high of $1.161 and a low of $0.29, indicating significant volatility. BiomX's market capitalization is approximately $7.7 million, reflecting its current valuation in the market. The trading volume on the AMEX exchange is 310,088 shares, showing active investor interest. The reverse stock split may impact these figures by potentially increasing the stock price and altering investor perception.
